Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine

Rheumatology

Volumn 43, Issue 1, 2004, Pages 13-18

  Clunie, Gavin P R ^a,b   Lennard, L ^a,b  

^a IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Azathioprine; Mercaptopurine; Myelosuppression; Thiopurine methyltransferase (TPMT)

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALLOPURINOL; AZATHIOPRINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; NUCLEOTIDE DERIVATIVE; OLSALAZINE; SALAZOSULFAPYRIDINE; SALICYLIC ACID; SALICYLIC ACID DERIVATIVE; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; XANTHINE OXIDASE;

ALLELE; ATOPIC DERMATITIS; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; COST CONTROL; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; ENZYME ACTIVITY; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HOSPITALIZATION; HUMAN; LEUKOPENIA; LIVER TOXICITY; MEDICAL DOCUMENTATION; MORBIDITY; NEUTROPENIA; PANCREAS DISEASE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SKIN TOXICITY; TREATMENT PLANNING;

6-MERCAPTOPURINE; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZATHIOPRINE; BIOLOGICAL MARKERS; ERYTHROCYTES; GENOTYPE; HUMANS; LEUKOPENIA; METHYLTRANSFERASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 0346463205     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keg442     Document Type: Review

References (90)

1. Gaffney K, Scott DGI, Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998;37:824-36.
2. Carette S, Klippel JH, Decker JL et al. Controlled studies on oral immunosuppressive drugs in lupus nephritis: A long-term follow-up. Ann Intern Med 1983;99:1-8.
3. Adu D, Pall A, Luqmani RA et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997;90:401-9.
4. Whisnant JK, Pelkey J. Rheumatoid arthritis: treatment with azathioprine (IMURAN R). Clinical side effects and laboratory abnormalities. Ann Rheum Dis 1982;41(Suppl. 1):44-7.
5. Pierce JC, Hume DM. Toxicity of azathioprine. Laval Med 1970;4:295-303.
6. Lennard L, Murphy MF, Maddocks JL. Severe megaloblastic anaemia associated with abnormal azathioprine metabolism. Br J Clin Pharmacol 1984;17:171-2.
7. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46:149-54.
8. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081-5.
9. Hoffmann M, Rychlewski J, Chrzanowska M, Hermann T. Mechanism of activation of an immunosuppressive drug: Azathioprine quantum chemical study on the reaction of azathioprine with cysteine. J Am Chem Soc 2001;123:6404-9.
10. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992;43:329-39.
11. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reactions of 6-mercaptopurine. Cancer Res 1974;34:738-46.
12. Marathias VM, Sawicki MJ, Bolton PH. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res 1999;27:2860-6.
13. Elion GB. Biochemistry and pharmacology of purine analogues. Fed Proc 1967;26:898-904.
14. Weinshilboum R, Raymond FA, Pazmino P. Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical properties. Clin Chim Acta 1978;85:323-3.
15. Weinshilboum RM, Sladek S. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Human Genet 1980;32:651-62.
16. Lewis RW, Olivier G. In vitro oxidation of 6-MP and its metallocomplexes by xanthine oxidase. Res Commun Chem Pathol Pharmacol 1977;18:377-80.
17. Lennard L, Lilleyman JS, Van Loon JA, Weishilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990;336:225-9.
18. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001-8.
19. Lowry P, Franklin CL, Weaver AL et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001;49:665-70.
20. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Aliment Pharmacol Ther 2002;16:389-98.
21. Kerstens PJSM, Stolk JN, Hilbrands LB et al, 5′-Nucleotidase and azathioprine related bone-marrow toxicity. Lancet 1993;342:1245-6.
22. Kerstens PJ, Stolk JN, De Abreu RA, Lambooy LH, van de Putte LB, Boerbooms AA. Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 1995;38:142-5.
23. Pieters R, Huismans DR, Veerman AJP. Are children with lymphoblastic leukaemia resistant to 6-mercaptopurine because of 5′-nucleotidase? Lancet 1987;2:1471.
24. Serre-Debeauvais F, Bayle F, Amirou M et al. Hematotoxicity caused by azathioprine genetically determined and aggravated by xanthine oxidase deficiency in a patient following renal transplantation. Presse Med 1995;24:987-8.
25. Guerciolini R, Szumlanski C, Weinshilboum RM. Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther 1991;50:663-72.
26. Saruwatari J, Nakagawa K, Shindo J et al. A population phenotyping study of three drug-metabolising enzymes in Kyushu, Japan, with use of the caffeine test. Clin Pharm Ther 2002;72:200-8.
27. Ghio AJ, Kennedy TP, Stonehuerner J et al. Iron regulates xanthine oxidase activity in the lung. Am J Physiol Cell Mol Physiol 2002;283:L563-72.
28. Farrell G, Tapner M. In vitro hepatoxicity of azathioprine at pharmacologic concentrations: Roles of xanthine oxidase, oxidative stress and mitochondrial injury [abstract 527]. J Hepatol 2002;36:146.
29. Goadsby PJ, Day RO, Kwan YL, Miners J, Birkett DJ. 6-Mercaptopurine-related leucopenia and in vivo xanthine oxidase activity. Lancet 1986;2:869-70.
30. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos 2001;29:601-5.
31. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects and dosage requirement in a thiopurine methyltransferase deficient child with cute lymphoblastic leukaemia. J Pediatr 1991;119:985-9.
32. Anstey A, Lennard L, Mayou SC, Kirby JD. Pancytopenia related to azathioprine - an enzyme deficiency caused by a common genetic polymorphism: A review. J R Soc Med 1992;85:752-6.
33. Schütz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in a thiopurine methyltransferase deficient heart transplant patient. Lancet 1993;341:436.
34. Ari ZB, Mehta A, Lennard L, Burroughs AK. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995;23:351-4.
35. Escousse A, Mousson C, Santona L et al. Azathioprine induced pancytopenia in homozygous thiopurine methyltransferase-deficient renal transplant recipients. Transplant Proc 1995;27:1739-42.
36. Leipold G, Schutz E, Haas JP, Oellerich M. Azathioprine-induced severe pancytopenia due to a homozygous two-point mutation of the thiopurine methyltransferase gene in a patient with juvenile HLA-B27-associated spondylarthritis. Arthritis Rheum 1997;40:1896-8.
37. Stolk JN, Boerbooms AM, de Abreu RA et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-66.
38. Szumlanski C, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: Possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995;39:456-9.
39. Lewis LD, Benin A, Szumlanski C et al. Olsalazine and 6-mercaptopurine-related hematologic suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
40. Woodson LC, Ames MM, Selassie CD, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol 1983;24:174-81.
41. Ames MM, Selassie CD, Woodson LC, van Loon JA, Hansch C, Weinshilboum RM. Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem 1986;29:354-8.
42. Griffin MG, Miner PB. Conventional drug therapy in inflammatory bowel disease. Gastroenterol Clin North Am 1995;24:509-21.
43. Hanauer SB. Drug therapy: Inflammatory bowel disease. N Engl J Med 1996;334:841-8.
44. Szumlanski C, Otterness D, Her C et al. Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterisation of a common polymorphism. DNA Cell Biol 1996;15:17-30.
45. Otterness D, Szumlanski C, Lennard L et al. Human thiopurine methyltransferase pharmacogenetics: Gene sequence polymorphisms. Clin Pharmacol Ther 1997;62:60-73.
46. Tai H-L, Krynetski EY, Scheutz EG, Yanishevski Y, Evans WE. Enhanced proteolysis of thiopurine methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): Mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci USA 1997;94:6444-9.
47. Evans WE. Comprehensive assessment of thiopurine S-methyltransferase alleles in three ethnic populations. J Pediatr Hematol Oncol 2002;24:335-6.
48. Hon YY, Fessing MY, Pui C-H et al. Polymorphisms of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 1999;8:371-6.
49. Ameyaw M-M, Collie-Duguid ESR, Powrie RH, Ofori-Adjei D, McLeod HL. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 1999;8:367-70.
50. McLeod HL, Pritchard SC, Githang'a J et al. Ethnic differences in thiopurine methyltransferase pharmacogenetics: evidence for allele specificity in Caucasian and Kenyan individuals. Pharmacogenetics 1999;9:773-6.
51. Chang J-G, Lee L-S, Chen C-M et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-East Asian populations. Pharmacogenetics 2002;12:191-5.
52. Hongeng S, Sasanakul W, Chuansumrit A et al. Frequency of thiopurine S-methyltransferase genetic variation in Thai children with leukaemia. Med Ped Oncol 2000;35:410-4.
53. Collie-Duguid ESR, Pritchard SC et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37-42.
54. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, 3B and 3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of the propositus. Br J Clin Pharmacol 2001;51:475-7.
55. Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: Molecular mechanisms and clinical importance. Pharmacology 2000;61:136-46.
56. Szumlanski CL, Honchel R, Scott MC, Weinshilboum RM. Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics 1992;2:148-59.
57. Lennard L, Singleton HJ. High performance liquid chromatographic assay of human red blood cell thiopurine methyltransferase activity. J Chromatogr B 1994;661:25-33.
58. Medard Y, Nafa S, Jacqz-Aigrain E. Thiopurine methyltransferase activity: new high-performance liquid chromatographic assay conditions. J Chromatogr B 1997;700:275-7.
59. Mayo Foundation Laboratory. Thiopurine methyltransferase measurement. Mayo Found Lab Med Bull 1991;14:1.
60. Krynetski EY, Tai H-L, Yates CR et al. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms. Pharmacogenetics 1996;6:279-90.
61. Yan L, Zhang S, Eiff B et al. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther 2000;68:210-9.
62. Lennard L, Welch J, Lilleyman JS. Intracellular metabolites of 6-mercaptopurine in children with lymphoblastic leukaemia: a possible indicator of non-compliance. Br J Cancer 1995;72: 1004-6.
63. Lafolie P, Hayder S, Bjork O, Peterson C. Intra-individual variation in 6-mercaptopurine pharmacokinetics during oral maintenance therapy of children with acute lymphoblastic leukaemia. Eur J Clin Pharmacol 1991;40:599-601.
64. Endresen L, Lie S, Stom-Methisen I, Rugstad HE, Stokke O. Pharmacokinetics of oral 6-mercaptopurine: Relationship between plasma levels and urine excretion of parent drug. Ther Drug Monit 1990; 12:227-34.
65. Lennard L, Singleton HJ. High performance liquid chromatographic assay of the methyl and nucleotide metabolites of 6-mercaptopurine: quantitation of red blood cell 6-thioguanine nucleotide, 6-thioinosinic acid and 6-methylmercaptopurine metabolites in a single sample. J Chromatogr 1992;583:83-90.
66. Bergan S, Bentdal O, Sodal G, Brun A, Rugstad HE, Stokke O. Patterns of azathioprine metabolites in neutrophils, lymphocytes, reticulocytes, and erythrocytes: relevance to toxicity and monitoring in recipients of renal allografts. Ther Drug Monit 1997;19:502-9.
67. Lavi LE, Holcenberg JS. A rapid high performance liquid chromatographic assay for 6-mercaptopurine metabolites in red blood cells. Anal Biochem 1985;144:514-21.
68. Hayder S, Lafolie P, Bjork O, Peterson C. 6-Mercaptopurine plasma levels in children with acute lymphoblastic leukaemia: Relation to relapse risk and myelotoxicity. Ther Drug Monit 1989; 11:617-22.
69. Koren G, Ferrazini G, Sulh H et al. Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukaemia in children. N Engl J Med 1990;323:17-21.
70. Erdmann GR, Chan GLC, Canafax DM. HPLC determination of 6-thiouric and 6-mercaptopurine in organ transplant patient serum. J Liquid Chromatogr 1988;11:971-81.
71. Chocair PR, Duley JA, Simmonds HA, Cameron JS. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant patients. Transplantation 1992;53:1051-6.
72. Snow JL, Gibson LE. The role of genetic variation in thiopurine methyltransferase activity and the efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995;131:193-7.
73. Murphy LA, Atherton D. A retrospective study of azathioprine in childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at risk of myelosuppression. Br J Dermatol 2002;147:308-15.
74. Regueiro M, Mardini H. Determination of thiopurine methyltransferase genotype or phenotype optimises dosing of azathioprine for the treatment of Crohn's disease. J Clin Gastroenterol 2002;35: 240-4.
75. Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1743-50.
76. Langley PG, Underhill J, Tredger M, Norris S, Mcfarlane IG. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002;37:441-7.
77. Black AJ, McLeod H, Capell HA et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716-8.
78. Naughton MA, Battaglia E, O'Brien S, Walport MJ, Botto M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 1999;38:640-4.
79. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: The cost effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002;29:2507-12.
80. Corominas H, Domenech M, Laiz A et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology 2002;42:1-6.
81. Seidman EG, Furst DE. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J Rheumatol 2002;29:2484-6.
82. Tavadia SMB, Mydlarski PR, Reis MD et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000;42:628-32.
83. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenetics. AAPS Pharmsci 2000;2:article 29 (www.pharmsci.org/).
84. Pickenpack A, Straub RH, Distler O et al. Safety and efficacy of an intravenous loading dose of azathioprine for treatment of non-TPMT-deficient patients with rheumatic diseases. Rheumatology 2000;39:1435-6.
85. Colombel JF, Ferrari N, Debuvsere H et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
86. Dubinsky MC, Lamothe S, Yang HY et al. Pharmacogenetics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
87. Schwab M, Schafflerar E, Marx C et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics; 2002;12:429-36.
88. Dubinsky MC, Yang HY, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002;122:904-15.
89. Ehrenfeld M, Shoenfeld Y. Haematological disorders in rheumatic disease. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology, 2nd edn. Oxford: Oxford University Press, 1998:290-7.
90. Lennard L. Clinical implications of thiopurine methyltransferase optimization of drug dosage and potential interactions. Ther Drug Monit 1998;20:527-31.